Affiliation:
1. Department of Neurochemistry, National Institute of Mental Health & Neurosciences, Bengaluru, India
2. Department of Psychiatry, National Institute of Mental Health & Neurosciences, Bengaluru, India
Abstract
Blood tests are in need, in the clinical diagnosis of Alzheimer’s disease (AD) as minimally invasive and less expensive alternatives to cerebrospinal fluid and neuroimaging methods. On these lines, single molecule array (Simoa) analysis of amyloid-β (Aβ42), total tau (t-tau), phospho-tau (p-tau 181), and neurofilament L (NfL) in the plasma samples of AD subjects, healthy controls (HC), and non-AD subjects was conducted. Findings from this study suggest that a panel of multiple plasma biomarkers (NfL, Aβ42, t-tau, and p-tau 181) combined with the clinical assessments could support differential diagnosis of AD and other dementias from healthy controls.
Reference19 articles.
1. Diagnostic biomarkers of amyloid and tau pathology in Alzheimer’s disease: An overview of tests for clinical practice in the United States and Europe;Laccarino;J Prev Alzheimers Dis,2023
2. Biomarkers of Alzheimer’s disease: Past, present and future clinical use;Georgakas;Biomark Neuropsychiatry,2023
3. Diagnostic accuracy of blood-based biomarker panels: A systematic review;Hardy-Sosa;Front Aging Neurosci,2022
4. Plasma neurofilament L to amyloid β42 ratio in differentiating Alzheimer’s type from non-Alzheimer’s dementia: A cross-sectional pilot study from India;Subramanian;Asian J Psychiatr,2021
5. Neurofilaments in disease: What do we know?;Gordon;Curr Opin Neurobiol,2020
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献